Filing Flows › Health Care › Cytokinetics (CYTK)
Cytokinetics (CYTK) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Cytokinetics (CYTK) Q3 2026 earnings results →
Q3 2026 Revenue up 2356% year over year to $47.6M · 400¢ of every $1 of revenue lost · operating margin -351.3%
Cytokinetics made $47.6M in Q3 2026 (25× Y/Y): Net Product Revenue $44.5M, Collaboration Revenues $3.0M. Operating margin -351.3%, net loss $190M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $47.6M in Q3 2026, up 2356% year over year and up 66% from the previous quarter. Net Product Revenue was the largest line at 94% of revenue. Collaboration Revenues added $1.1M year over year (up 58%), 2% of the total change.
Operating costs exceeded revenue by $167.1M, an operating margin of -351.3%. Total costs grew 27% against revenue growth of 2356%. The fastest-growing cost line was SG&A (+63%). The quarter ended with a net loss of $190.1M, narrower than the previous quarter's $198.8M loss.
Operating cash flow was −$124.0M. Non-cash charges added back $3.6M of depreciation and amortization and $34.7M of share-based compensation. Working capital and other items added $27.7M. Capital expenditures of $700K exceeded it, leaving free cash flow of −$124.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $47.6M | 25× | -351.3% | −$190M | −$124M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $28.6M | -57% | -626.0% | −$199M | −$160M |
| Q1 2026 | 10-Q | May 5, 2026 | $19.4M | 12× | -948.7% | −$206M | −$145M |
| Q4 2025 | 10-K | Feb 26, 2026 | $17.8M | +5% | n/m | −$183M | −$143M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $1.9M | +318% | n/m | −$306M | −$108M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $66.8M | 268× | -167.0% | −$134M | −$128M |
| Q1 2025 | 10-Q | May 6, 2025 | $1.6M | +89% | n/m | −$161M | −$132M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cytokinetics
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our first commercial product is MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, and 20 mg tablets, which the FDA approved in December 2025. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. The approval of MYQORZO included a risk evaluation and mitigation strategy (REMS) program to ensure the benefits of the drug outweigh the risk of heart failure due to systolic dysfunction.
In its own words, from its 10-K, filed Feb 26, 2026.
Cytokinetics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 25× against the peers' median +10%. Operating margin: -351.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CYTK Cytokinetics | Q3 2026 | $47.6M | 25× | -351.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Cytokinetics 10-Q on SEC EDGAR · CIK 1061983 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns CYTK and who is buying
More on CYTK
- How Cytokinetics makes money: revenue by segment
- Cytokinetics next earnings date and what analysts expect
- Cytokinetics stock forecast, price target and fair value
- Who owns Cytokinetics stock: holders, funds and Congress trades
- Cytokinetics guidance and outlook
- Is Cytokinetics a takeover target? LBO and rumors
- Cytokinetics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results